NCT06093425: An ongoing trial by Suzhou Transcenta Therapeutics Co., Ltd.
This trial is ongoing. It must report results 4 years, 7 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06093425 |
|---|---|
| Title | A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating Combination of TST001, Pembrolizumab and Chemotherapy as First-Line Treatment in Subjects With Claudin18.2 Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 30, 2026 |
| Completion date | Oct. 1, 2029 |
| Required reporting date | Oct. 1, 2030, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Feb. 27, 2026 |
| Days late | None |